Payment overview · 2025
General Payments
$367.97
14 reported records · 9 companies
Healthcare provider profile · identity verified
Nancy Ellen Jolly, MD
Allopathic & Osteopathic Physicians|Family Medicine · CADIZ, KY · NPI 1962905950
Verified facts
What the public records show
CMS Open Payments records show Nancy Ellen Jolly, MD received $367.97 in general payments during 2025 across 14 reported records.
Axsome Therapeutics, Inc. accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Farxiga, Mounjaro, Quviviq.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Auvelity by this doctor in 2024.
IDORSIA PHARMACEUTICALS US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUVIVIQ as an associated drug or biological on 2281 records involving 1911 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Quviviq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 34.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.41 | 18.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.22 | 11.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.20 | 9.0% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $31.56 | 8.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.51 | 5.6% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $17.31 | 4.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.12 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.64 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $367.97 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.57 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.21 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.20 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $31.56 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Quviviq quviviq |
2025 | Quviviq | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| IDORSIA PHARMACEUTICALS US INC Exact reporting entity; no affiliate inference |
2025 | QUVIVIQ open payments reported associated product |
CMS Open Payments — General Payments 2281 supporting records · 1911 recipient NPIs · example record 1243392023 |
Quviviq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 353 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 79 |
| Gabapentin | Gabapentin | 254 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 234 | 66 |
| Lisinopril | Lisinopril | 208 | 61 |
| Losartan Potassium | Losartan Potassium | 200 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 171 | 53 |
| Furosemide | Furosemide | 156 | 46 |
| Omeprazole | Omeprazole | 156 | 49 |
| Famotidine | Famotidine | 141 | 40 |
| Meloxicam | Meloxicam | 136 | 43 |
| Eliquis | Apixaban | 122 | 27 |
| Montelukast Sodium | Montelukast Sodium | 119 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 35 |
| Trazodone Hcl | Trazodone Hcl | 116 | 32 |
| Simvastatin | Simvastatin | 114 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 31 |
| Tramadol Hcl | Tramadol Hcl | 106 | 21 |
| Metformin Hcl | Metformin Hcl | 104 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 39 |
| Alprazolam | Alprazolam | 97 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 31 |
| Potassium Chloride | Potassium Chloride | 95 | 32 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 86 | 16 |
| Carvedilol | Carvedilol | 83 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 26 |
| Ozempic | Semaglutide | 74 | 12 |
| Allopurinol | Allopurinol | 61 | 17 |
| Buspirone Hcl | Buspirone Hcl | 61 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 58 | 20 |
| Farxiga | Dapagliflozin Propanediol | 57 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 17 |
| Jardiance | Empagliflozin | 56 | 17 |
| Sertraline Hcl | Sertraline Hcl | 56 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 16 |
| Glipizide Er | Glipizide | 52 | 14 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Methylprednisolone | Methylprednisolone | 50 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 13 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 18 |
| Metformin Hcl Er | Metformin Hcl | 45 | 12 |
| Donepezil Hcl | Donepezil Hcl | 42 | 14 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Atenolol | Atenolol | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 28 |
| Estradiol | Estradiol | 34 | 15 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | 14 |
| Fluconazole | Fluconazole | 32 | 12 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Kerendia | Finerenone | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 11 |
| Nystatin | Nystatin | 31 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 11 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 15 |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Finasteride | Finasteride | 26 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Naproxen | Naproxen | 24 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $367.97 · 14 records | Axsome Therapeutics, Inc. | Auvelity, FARXIGA, MOUNJARO, NURTEC ODT, OTEZLA, Quviviq, REPATHA, Senza, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error